研究人员选择研究Semaglutide作为潜在治疗方法，因为这一类药物有助于减少MASH患者的脂肪和肝脏疤痕。Newsome教授此前在《柳叶刀》和《新英格兰医学杂志》上发表的小规模积极研究表明，使用Semaglutide治疗MASH对患者有益。

最新发表在《新英格兰医学杂志》的里程碑研究显示，胰高血糖素样肽-1(GLP-1)受体激动剂司美格鲁肽(semaglutide)在对抗代谢功能障碍相关脂肪性肝炎(MASH)战役中取得重大突破。这项覆盖37个国家800名患者的3期临床试验揭示，每周皮下注射2.4 mg剂量组患者中 ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...

New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

According to a new major clinical trial known as the ESSENCE trial, semaglutide—better known as Ozempic when used for Type 2 diabetes, or Wegovy when prescribed for weight loss—may be doing more for ...

The diabetes and weight loss drug semaglutide reversed liver scarring and inflammation. It’s among several drugs in the works for the condition MASH.

More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A reduction in liver fibrosis stage was observed among 36.8% of the semaglutide group.